Interviews

At the IVBM Charlotte event, Seungjean Chai, MD, emphasized that patient-centered design, guidelines, and subspecialty expertise are essential to high-value oncology care.

Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.

Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.

Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.

With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Community-academic collaboration can reduce access burdens and strengthen continuity of care, says Anasuya Gunturi, MD, PhD.

Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

Catchment areas, access, and partnerships influence diversity in oncology trials, Amir Fathi, MD, explains at a Boston IVBM panel.